Contributor:

Charles C. Wykoff, MD, PhD, Harry Flynn MD

Angiogenesis 2021: Early Phase Data

John Kitchens, MD; Nadia Waheed, MD; and Charles Wykoff, MD, PhD

COVID-19: Can Clinical Trials Proceed?

John Kitchens, MD; Namrata Saroj, OD; Jeffrey Heier, MD; Carl Regillo, MD; and Charles Wykoff, MD, PhD

Suprachoroidal Steroids for DME

Charles Wykoff, MD, PhD

COVID-19: Can Clinical Trials Proceed?

Jeffrey Heier, MD, Carl D. Regillo, MD, FACS, Charles C. Wykoff, MD, PhD, FACS, John Kitchens, MD, Namrata Saroj, OD

Long-term Anti-VEGF Therapy for DME

Timothy Murray, MD, MBA, Charles C. Wykoff, MD, PhD

Looking Deeper on OCT

Brandon Lujan, MD, Charles C. Wykoff, MD, PhD, FACS

Innovations in Geographic Atrophy

I. Paul Singh, MD; and Charles C. Wykoff, MD, PhD, FACS

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

27-Gauge Talk

Charles C. Wykoff, MD, PhD, Yoshiro Yonekawa, MD

ABC to Block VEGF-A Isoforms

Charles C. Wykoff, MD, PhD

A Role for Biosimilars in Retina?

Alay S. Banker, MD, Charles C. Wykoff, MD, PhD, FACS

Now Is the Time to Embrace DAVS

Charles C. Wykoff, MD, PhD, Rishi Singh, MD

Key Points From the Phase 3 PANORAMA Study

Charles C. Wykoff, MD, PhD, FACS